

Development of therapeutic autologous vaccine against acute myeloid leukemia

Seoul National University



ONCOLOGY	Hit
Product Type	Vaccine
Indication	Acute Myeloid Leukemia
Target	<ul style="list-style-type: none"> • AML-specific T cells
MoA(Mechanism of Action)	Autologous vaccine induces AML-specific T cell immunity in vivo
Competitiveness	<ul style="list-style-type: none"> • It is hard to define tumor-antigen in AML due to its heterogenous nature, which makes it hard to develop vaccine against AML • Our vaccine platform offers a simple, cost-effective autologous AML vaccine that induces AML-specific T cell immunity in vivo
Development Stage	Hit
Route of Administration	Intravenous